News
IXICO webinar session; Using MRI to assess safety, efficacy and eligibility of new Alzheimer's Disease therapies. This Webinar is now over. “We were overwhelmed with the turnout and level of participation”.Ciaran Cooper. VP Business Development.
A re-run of this session will be announced soon.
For more information Click here
"Working with our customers, we can unlock imaging's potential to accelerate and reduce the costs of product development, and hence give more patients earlier access to effective and safe treatments."
Prof Derek Hill,
CEO, IXICO
New article
Expert Opinion on Investigational Drugs - by Derek Hill, CEO
The North American Alzheimer's Disease Neuroimaging Initiative, and similar activities in Europe, Japan, and Australia, are natural history studies that are providing new insights into the use of imaging end points in clinical trials. See the article here.